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Background: Common variable immunodeficiency (CVID) is the most common clinically
severe primary immunodeficiency and comprises a heterogeneous group of patients
with recurrent severe bacterial infections due to the failure to produce IgG antibodies
after exposure to infectious agents and immunization. Diagnostic recommendations for
antibody failure include assessment of isoagglutinins. We have readdressed this four
decades old but still accepted recommendation with up to date methodology.
Methods: Anti-A/B IgM- and IgG-antibodies were measured by Diamed-ID Micro Typing,
surface plasmon resonance (SPR) using the Biacore® device and flow cytometry.
Results: When Diamed-ID Micro Typing was used, CVID patients (n=34) showed IgG-
and IgM-isoagglutinins that were comparable to healthy volunteers (n=28), while all XLA
patients (n=8) had none. Anti-A/B IgM-antibodies were present in more than 2/3 of the
CVID patients and showed binding kinetics comparable to anti-A/B IgM-antibodies from
healthy individuals. A correlation could be found in CVID patients between levels of anti-
A/B IgM-antibodies and levels of serum IgM and PnP–IgM-antibodies. In contrast in CVID
patients as a group ABO antibodies were significantly decreased when assessed by SPR,
which correlated with levels of switched memory, non-switched memory and naïve B
cells, but all CVID patients had low/undetectable anti-A/B IgG-antibodies.
Conclusion: These results indicate that conventional isoagglutinin assessment and
assessment of anti-A/B IgM antibodies are not suited for the diagnosis of impaired
antibody production in CVID. Examination of anti-A/B IgG antibodies by SPR provides
a useful method for the diagnosis of IgG antibody failure in all CVID patients studied, thus
indicating an important additional rationale to start immunoglobulin replacement therapy
early in these patients, before post-infectious sequelae develop.
Keywords: blood groups, isoagglutinins, common variable immunodeficiency, B cell subsets, anti-ABO antibodies,
pneumococcal polysaccharide, natural antibodies
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Introduction
Common variable immunodeficiency (CVID) is a heterogeneous
disorder belonging to the group of primary antibody deficien-
cies, characterized by markedly reduced serum levels of IgG,
IgA, and often IgM, and a substantial failure to produce specific
IgG antibodies after vaccination or exposure to foreign antigens
(1–5). This renders patients susceptible to recurrent sinopul-
monary, ear, and gastrointestinal infections, the underlying reg-
ulatory immune defect can lead to autoimmune diseases, and
certain malignancies may occur more frequently. Several mono-
genetic defects including homo/heterozygous mutations in ICOS
(inducible costimulator of activated T cells), TACI (transmem-
brane activator and calcium-modulator and cyclophilin ligand
interactor), BAFF-R (B cell activating factor receptor), CD19,
CD81, and Msh5 were found in CVID patients, but genetics
of CVID are complicated by unaffected relatives that carry the
same mutations showing that the genotype–phenotype correla-
tion can be variable (6). For the majority of CVID patients, how-
ever, the underlying molecular defect has not yet been defined.
Immunological abnormalities including defects in antigen pre-
sentation by monocytic cells and perturbed differentiation, matu-
ration, and function of DCs and invariant NK (iNK) cells were
described (7, 8). In addition to intrinsic B cell defects (9, 10)
functional abnormalities in T cells which can potentially lead
to defects in memory B cell compartment were described, and
included impaired early signaling events, production of cytokines
and expression of activation markers after antigenic stimula-
tion (11, 12).
Early IUIS, ESID/PAGID, and recent ESID diagnostic cri-
teria of CVID include poor antibody response to polypeptide
and polysaccharide vaccines and absence of anti-blood group
A (anti-A) and B (anti-B) antibodies as equivalent criteria (3–
5). However, studies addressing the question whether CVID
patients have defective production of isoagglutinin antibodies
examined in an isotype-specific manner are scarce. The immuno-
logically active epitopes of blood group ABO antigens share
carbohydrate moieties (13). Blood group A/B specific antibod-
ies are produced by all individuals with a functional immune
system and are included under the broad classification of ‘nat-
ural antibodies’ in humans (14). They appear first in infants
at the age of 3–6month when the developing immune system
can react with microorganisms and environmental antigens that
have carbohydrate epitopes similar to the blood group ABO
antigens (13, 14). The aim of the present study was to inves-
tigate whether freshly diagnosed CVID patients, who hitherto
had not received IVIG treatment, show a defect in anti-A/B
IgG or IgM antibodies. We used three different techniques, the
DiaMed-ID Micro Typing System, a blood group ABO flow
cytometry based assay (15), and the surface plasmon resonance
technology (SPR) using the Biacore® device and synthetic AB
trisaccharides (16–18) to study the blood group anti-A/B IgG
and IgM antibody titer in an isotype-specific assay and the
on/off rates of the binding of the respective antibodies to defined
blood group A/B trisaccharides in CVID patients and healthy
individuals.
Materials and Methods
CVID Patients and Healthy Controls
Thirty-four patients with CVID diagnosed according to the cri-
teria established by the IUIS expert committee (5) were included
in the study after informed consent was obtained. The immuno-
logical characterization of the patients is depicted in Table 1.
The study was conducted according to guidelines of the Medical
University of Vienna (MUW) and was approved by the ethic
commission of the MUW. The patients gave their informed
consent that anonymized data collected as part of the routine
medical attendance the patients received could be included in
a scientific publication. All results presented in this study were
obtained as part of the routine medical attendance the patients
received, no extra venipuncture was performed on the basis of this
study. Serum samples of CVID patients were drawn before regular
intravenous IVIG substitution therapy was started. Twenty-eight
healthy adult blood donors and eight X-linked primary antibody
deficiency (XLA) patients with no B cells and complete absence
of immunoglobulins of all isotypes due of a defect in bruton’s
tyrosine kinase (btk) served as positive and negative controls
(individuals with blood group ABwere not included in the study).
The distribution of ABO blood group among the controls (blood
group [N]: O [16], A [7], B [5], AB [0]) was not significantly
different as compared to the CVID patients (Table 1; P= 0.1, Chi-
squared analysis). All serum samples were immediately separated
from peripheral blood, dispensed into 500 µl aliquots and stored
until analysis at –30°C. IgG from plasma of eight healthy subjects
with known history of high anti-A/B antibodies was depleted
using a protein A column first and subsequently a Protein G
column (Enchant™ IgG purification and depletion Kit, Pall Life
Science, Port Washington, NY, USA) in order to obtain IgM
antibodies only. The amount of IgM as well as IgG contamination
was determined by ELISA.
Determination of Anti-A/B Antibodies by the
DiaMed-ID Micro Typing System
Anti-A/B antibodies were determined by the Diamed-ID Micro
Typing System (DiaMed AG, Cressier, Switzerland) according to
the manufacturer’s protocol. The ID-Card 50520 (NaCl) was used
to measure IgM, while the ID-Card 50531 (LISS/Coombs con-
taining polyspecific anti-human gammaglobulin [AHG] serum)
could determine IgG in addition to IgM. The serum samples were
serially diluted with 0.9% saline solution starting at 1:2, 1:4, until
1:265, and 25 µl of each dilution was pipetted into a single column
of the microtube gel card together with 50 µl of DiaMed ID-
DiaCell ABO/I–II test cell suspensions A1 or B (DiaMedAG). The
ID-Cards (NaCl) were subsequently incubated at room temper-
ature for 15min, the ID-Cards (LISS/Coombs) at 37°C and then
centrifuged in aDiaMed ID-Centrifuge 24 s for 10min at 910 rpm.
Results were read immediately after centrifugation, the titer that
led to visible agglutination of erythrocytes dispersed in the gel was
selected positive. If an individual showed both anti-A and anti-
B antibodies then the higher titer of the two values was used for
statistical analysis.
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TABLE 1 | Immunological characterization of CVID patients.
Patient
number
Sex Agea ABO blood
group
Serum immunoglobulins
(mg/dl)a
PnP antibodies
(reciprocal titer)b
CD19+
(% ly)c
% of CD19-positive
lymphocytes
IgG IgA IgM PnP–IgG PnP–IgM CD27+
IgD 
CD27+
IgD+
CD27 
IgD+
1 m 29 A 223 6 5 <20 <20 6 1,48 5,33 84,68
2 m 40 A 86 <6 12 <20 <20 6 4,75 6,27 83,17
3 m 47 A 160 6 4 21 <20 7 4,67 20,46 70,29
4 f 36 O 48 <7 <6 <20 <20 8 0,38 0,98 94,03
5 f 52 n.a. <7 <6 12 <20 <20 4 n.a. n.a. n.a.
6 f 48 n.a. 12 6 8 <20 <20 14 1,60 29,73 66,40
7 m 27 B 22 <6 <5 <20 <20 0 n.a. n.a. n.a.
8 f 49 O 94 6 23 <20 <20 5 0,66 4,80 91,95
9 f 29 O 169 <8 <7 63 <20 15 n.a. n.a. n.a.
10 f 54 O 199 <8 49 63 35 18 1,63 16,86 79,52
11 f 34 B 239 <8 47 <20 40 12 2,49 11,77 84,42
12 m 39 A 111 <7 <6 n.a. n.a. 9 n.a. n.a. n.a.
13 m 10 O 365 <5 17 <20 20 14 1,94 9,28 85,78
14 m 39 O 288 7 6 99 <20 13 1,60 41,62 49,28
15 m 50 O <158 59 171 <20 49 18 n.a. n.a. n.a.
16 f 30 O 179 36 252 39 121 8 0,68 48,39 49,26
17 f 57 A 204 11 34 <20 30 20 14,52 17,86 62,60
18 m 33 A 84 <7 9 <20 <20 20 0,39 1,68 96,69
19 m 64 A 89 11 11 <20 36 3 n.a. n.a. n.a.
20 m 32 A 9 6 4 <20 <20 13 n.a. n.a. n.a.
21 f 44 A 219 44 26 <20 <20 5 n.a. n.a. n.a.
22 f 57 A 197 <8 <7 n.a. n.a. 6 n.a. n.a. n.a.
23 m 20 A <148 <8 <6 <20 <20 5 1,80 6,10 87,02
24 m 42 O 60 <7 <4 <20 <20 15 8,91 29,57 59,65
25 m 13 A 76 <8 50 <20 <20 14 n.a. n.a. n.a.
26 m 27 A <148 <8 41 39 <20 11 1,98 28,37 62,33
27 m 25 O 10 <6 8 <20 <20 13 0,77 25,32 73,26
28 f 10 O 383 356 76 <20 <20 5 n.a. n.a. n.a.
29 m 50 A <7 <6 <5 <20 <20 3 2,75 9,89 84,07
30 m 19 O 210 <6 39 <20 <20 12 0,93 4,34 91,09
31 f 21 O 295 46 30 <20 117 10 1,35 7,72 89,37
32 m 22 A 154 13 31 n.a. n.a. 10 1,83 14,05 83,28
33 f 47 A 201 9 33 <20 50 13 1,90 15,81 80,98
34 m 17 O <7 <6 <5 <20 <20 0 n.a. n.a. n.a.
Normal
range
815–1784 93–287 108–237 >200 >100 7–23 9–36 6–32 37–77
aAt time of diagnosis, before the initiation of immunoglobulin replacement therapy.
bSerum IgG- and IgM-antibodies against 23-valent pneumococcal polysaccharides (PnP) were determined by ELISA before the initiation of immunoglobulin replacement therapy.
cPercentage of peripheral blood CD19-positive lymphocytes as determined by flow cytometry.
n.a., Data not available.
Flow Cytometric Analysis of Patients’ Anti-A/B
Antibodies and B Cell Populations
Undiluted serum samples of CVID patients and healthy control
subjects were incubated for 30min at 4°C with 1% solution of
fixed RBCs (15). Thereafter, cells were washed two times in
FACS buffer (Hank’s buffered salt solution with 0.1% BSA) and
bound anti-A/B antibody to test erythrocytes was measured by
flow cytometry using either a DyLight 649 conjugated affinity
purified Fab fragment goat anti-human IgM (Fc5µ fragment spe-
cific, 15 µg/ml, Jackson ImmunoResearch Ltd, Newmarket, UK)
or a DyLight 649 conjugated affinity purified F(ab0)2 fragment
rabbit anti-human IgG (Fc
γ
fragment specific, 60 µg/ml, Jackson
ImmunoResearch). A minimum of 10, 000 events was acquired.
All analysis were performed on a BD FACSCanto™(Becton Dick-
inson, Franklin Lakes, NJ, USA) interfaced to BD FACSDiva™
software. Mean fluorescence intensity (MFI) was calculated and
represented the titer of anti-A/B IgG or IgM antibodies present in
the sample. If an individual sample showed both anti-A and anti-
B IgG and IgM antibodies then the higher MFI-titer of the two
values was used for statistical analysis. Lymphocyte subpopula-
tions and B cell subsets were analyzed in peripheral whole blood
by flow cytometry using standard protocols with commercially
available directly conjugated monoclonal antibodies (anti-CD19
PerCP, Becton Dickinson Austria Ges.m.b.H., Schwechat, Austria;
anti-IgD FITC, Becton Dickinson Austria Ges.m.b.H., anti-CD27
PE, eBioscience, Vienna, Austria) and a FACSCalibur (Becton
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Dickinson Austria Ges.m.b.H.). Data analysis was performed
using CellQuest software (Becton Dickinson Austria Ges.m.b.H.).
Determination of Anti-A/B Antibodies by Surface
Plasmon Resonance
The erythrocyte aggregation assay based on theDiamed-IDMicro
Typing System as well as the flow cytometric method to quantify
binding of anti-A/B IgG or IgM antibodies to fixed human A or
B red blood cells (ABO-FACS) are semi-quantitative assays that
lack sensitivity and specificity to precisely rank anti-A/B IgG and
IgM antibodies according to their strength of reaction with the
corresponding blood groupA/B trisaccharide antigens. Therefore,
we used SPR to measure the association rate (ka) of the anti-
A/B IgG and IgM antibodies to the immobilized synthetic blood
group A or B trisaccharides and their dissociation rate (kd) on a
Biacore X device (16–18). We used the dextran hydrogel layer on
the CM-5 sensor chip to form a hydrophilic environment for the
attachment of blood group A or B trisaccharide amine derivative,
preserving the blood group antigens in a non-denatured state (18).
This allows for measurement of antigen–antibody binding under
almost physiological conditions. Amine-labeled blood group A
and B trisaccharides (Dextra Laboratories Ltd., Reading, UK)
were immobilized on CM5 sensor chips (Biacore, GE Health-
care) according to standard protocols (16). In brief, the CM-5
sensor chip surface was activated with 100 µl of 0.05mol/l N-
hydroxysuccinimide (Sigma Aldrich, St. Louis, MO, USA) and
0.2mol/l N-ethyl-N’-dimethylamino propylcarbodiimide (Sigma
Aldrich) injected into the buffer stream of HBS-EP (0.01mol/l
HEPES buffer, pH 7.4, containing 0.15mol/l NaCl, 3mmol/l
EDTA, and 0.005% surfactant P20). The buffer stream was passed
through FC-1 and FC-2 of the Biacore X instrument (GE Health
Care, Uppsala, Sweden) at a flow rate of 5 µl/min for 20min.
Subsequently, 15 µl of a blood group A/B trisaccharide amine
derivative solution at a concentration of 1mg/ml, prepared with
borate (pH 8.5), was injected into the buffer stream and passed
through FC-1 at a flow rate of 5 µl/min and was halted after
injection of 7 µl for 2 h. Residual active ester groups on the sen-
sor surface were then deactivated by injecting 100 µl of 1mol/l
ethanolamine-HCl (pH 8.5) into the buffer stream and passing it
through FC-1 and FC-2, and by passing the buffer stream through
the cell until a stable baseline was achieved. To measure anti-
A/B antibodies, crude human serum was diluted by half with the
HBS-EP and 100 µl of the diluted plasma samples were passed
through FC-1 and FC-2 at a flow rate of 20 µl/min for 5min.
When the association phase was finished, the flow cell was washed
for 20 s with the HBS-EP buffer and dissociation was recorded
in resonance units (RU) at a flow rate of 20 µl/min for 20min.
The chip was regenerated after each measurement in order to
reach the same baseline level as prior to measurement by remov-
ing bound antibody with 50 µl of 50mmol/l NaOH buffer at a
flow rate of 60 µl/min. To establish a calibration curve for anti-
A/B antibody concentration, BIAevaluation software (General
Electric Healthcare) was used. The amount of anti-A or anti-B
antibody that associated with the corresponding blood group A
or B trisaccharide immobilized on the sensor chip surface was
obtained by subtracting the FC-II value (RU) from the FC-I value
(RU). If an individual showed both anti-A and anti-B antibodies
then the higher of the two RU values was used for statistical
analysis.
Isotype-Specific Determination of Anti-A/B
Antibodies by Surface Plasmon Resonance
To measure anti-A/B IgG and IgM antibodies, crude human
serum was diluted by half with the HBS-EP and 100 µl of
the diluted plasma samples were passed through FC-1 and
FC-2 at a flow rate of 20 µl/min for 5min. To discriminate
between anti-A/B IgM and IgG response, anti-human IgG Abs
(Coombs serum, Diamed) were injected first after the associ-
ation phase was finished, followed by injection of anti-human
IgM mAbs (Sigma Aldrich). The increase in RU following
the injection was indicative for the amount of IgG or IgM
bound to the synthetic trisaccharides. If an individual showed
both anti-A and anti-B IgG or IgM antibodies then the speci-
ficity with the higher titer (anti-A or anti-B) of the respec-
tive immunoglobulin isotype was used for statistical analysis.
Before analysis was started, the binding of commercially avail-
able anti-blood group A/B antisera (anti-A murine monoclonal
Abs clone MH04 and A3D3, anti-B murine monoclonal Abs
clone NB1.19, NB10.5A5, and NB10.3B4, Ortho-Clinical Diag-
nostics, Neckargmünd, Germany) to the respective trisaccha-
rides was measured in order to examine chip performance.
Serial dilutions of anti-blood group A mAbs (IgG clone 9A,
Abcam, Cambridge, MA, USA) and anti-blood group A/B anti-
sera (Ortho-Clinical Diagnostics) were performed to generate a
dose-dependent curve.
Measurement of Serum Immunoglobulins and
Serum Antibodies against Pneumococcal
Polysaccharides
Serum concentrations of IgG, IgA, and IgM were deter-
mined by laser nephelometry using reagents purchased from
Siemens–Behring Division (Siemens Healthcare Diagnostics
GmbH,Vienna, Austria). Serum levels of IgG- and IgM-antibodies
against 23-valent pneumococcal capsular polysaccharide were
determined using an in-house produced ELISA detecting all
serotypes contained in the 23-valent PnP vaccine as previously
described (19, 20).
Statistical Analysis
The non-parametric Mann–Whitney U-test (two-sided P value)
was used for unpaired comparison of results obtained from
patients and healthy control subjects. A P value of <0.05 was
assumed to be statistically significant. The Bravais–Pearson-
correlation coefficient was calculated to determine a statisti-
cally significant correlation between two parameters at a level
of P< 0.05. Where results are depicted using box plot dia-
grams, the median of the study group is represented by a
cross, the interquartile range (IQR) is represented by the box,
5- and 95-percentile values are represented by the whiskers,
and minimum and maximum values are represented by cir-
cles. The 95% confidence interval for the median calculated
according to McGill et al. (21) is indicated by horizon-
tal bars.
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Results
Blood Group Anti-A/B Antibodies did not Differ
Between CVID Patients and Healthy Individuals
When Determined by Diamed-ID Micro Typing
When the amount of anti-A/B antibodies in samples of 34 CVID
patients, diagnosed according to the criteria established by the
IUIS expert committee (5), was determined by the Diamed-ID
Micro Typing System using the ID-Card 50520 (NaCl) to mea-
sure IgM-isoagglutinins, no difference could be found between
CVID patients and healthy individuals (Figure 1A, left panel).
X-linked agammaglobulinemia (XLA) patients with a defect in
btk showed no detectable isoagglutinin antibodies (Figure 1A, left
panel).When sampleswere further analyzed in the ID-Card 50531
(LISS/Coombs containing polyspecific AHG serum) to determine
IgG- in addition to IgM-isoagglutinins, the isoagglutinin titers
detected were higher as compared to the NaCl-system, but still
no difference was observed between CVID patients and controls
(Figure 1A, right panel).
Surface Plasmon Resonance Analysis Shows
Defective ABO Blood Group Antibody Formation
in CVID Patients
In the erythrocyte aggregation assay based on the Diamed-ID
Micro Typing System, 4/28 (14%, NaCl system) and 3/28 (11%,
LISS/Coombs system) of the healthy volunteers had low to unde-
tectable (serum titer 1:2) isoagglutinin antibodies (data not
shown). To better detect anti-A/B antibodies, SPR technology
using synthetic blood group A/B trisaccharides coupled to the
CM-5 sensor chip by amine binding was employed (16–18).
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FIGURE 1 | Examination of anti-A/B antibodies in CVID patients,
patients with XLA and healthy controls using the Diamed-ID Micro
Typing System with the ID-Card 50520 (NaCl) to measure IgM
isoagglutinins [(A), left panel] or with the ID-Card 50531
(LISS/Coombs containing polyspecific AHG serum) to determine IgG-
in addition to IgM-isoagglutinins [(A), right panel] and surface
plasmon resonance (SPR) technology without identification of the
antibody isotype using synthetic blood group A/B trisaccharides
coupled to the CM-5 Biacore® chip by amine binding (B). Reciprocal
serum isoagglutinin titers [(A), left panel, IgM isoagglutinins; (A), right panel,
IgG and IgM isoagglutinins] and SPR resonance units (B) are depicted using
box plot diagrams, the median of the study group is represented by a cross,
the interquartile range (IQR) is represented by the box, 5- and 95-percentile
values are represented by the whiskers, and minimum and maximum values
are represented by circles. The 95% confidence interval for the median
calculated according to McGill et al. (21) is indicated by horizontal bars. The
non-parametric Mann–Whitney U-test (two-sided P value) was used for
statistical comparison between patients and healthy controls.
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This technology uses a molecularly defined carbohydrate anti-
gen and allows for real-time analysis of molecular interactions
of unlabeled antigen and antibody, thus leaving the functional
structures of both interaction partners intact. Furthermore, the
amine-labeling technology allows immobilization with a con-
trolled orientation for the carbohydrates (18). Thus the sensitivity
of detection of anti-A/B antibodies is enhanced by SPR tech-
nology (16). Accordingly, in those healthy individuals where no
or very low detectable anti-A/B titer could be observed in the
DiaMed-ID Micro Typing System and no binding of anti-A/B
specific antibodies to erythrocytes could be detected in the flow
cytometry based assay (data not shown), SPR showed slight but
detectable binding (100–130 RU) of anti-A/B antibodies to blood
group A/B tri-saccharides, and 27/27 (100%) of healthy individ-
uals had anti-AB antibody titers above 100 RU (Figure 1B). In
contrast to the isotype-specific SPR assay employed in later exper-
iments, the isotype of the anti-A/B antibodies was not identified
in these analyses.
In contrast to the findings obtained using theDiamed-IDMicro
Typing System, serum titers of anti-A/B antibodies as detected by
SPRwere significantly decreased in CVID patients as compared to
healthy controls (Figure 1B). In 22/31 CVID patients (in whom
both assays could be performed in parallel) anti-A/B antibodies
were detectable in the erythrocyte aggregation assay, and these
patients also showed antibody binding to the A/B trisaccharides
immobilized on the surface of the chip as indicated by SPR-RU,
although with a significantly decreased titer. The remaining nine
patients showed no visible aggregation in the Diamed-ID Micro
System and also showed no or only very low antibody binding
to the trisaccharides (RU well below 100). There was a positive
correlation between the patients’ decreased levels of anti-A/B
antibodies as detected by SPR and decreased levels of switched
memory B cells and IgM memory B cells, and patients with low
anti-A/B IgM antibodies had higher levels of naïve B cells, thus
showing that SPR anti-A/B antibodies are decreased in parallel
with other parameters indicative of the defect in B cell function
present in CVID patients (Figure 2).
CVID Patients Produce No Blood Group Anti-A/B
IgG as Examined by Flow Cytometry
To further discriminate between blood group anti-A/B IgM-
and IgG-antibodies, patients’ samples were analyzed by a semi-
quantitative assay to detect ABO blood group antibodies by
flow cytometry in an isotype-specific manner (15). The anti-A/B
IgG and IgM MFI histograms of a representative CVID patient
and a representative healthy control are given in Figures 3A–D,
where the X-axis represents the MFI given on a logarithmic
scale and the Y-axis the cell number on a linear numeric scale.
The filled histograms represent binding of an anti-A/B-negative
control sample (AB serum), the bold lines (CVID) and hatched
histograms (healthy control) represent the binding of IgM/IgG
antibodies present in the tested serum that react with human
red blood cells (RBCs). A statistically significant impairment
in anti-A/B IgG formation was detected in CVID patients as
compared to healthy controls (Figures 3A,B,E), while anti-A/B
IgM-antibody titers were comparable between CVID patients and
controls (Figures 3D,F).
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FIGURE 2 | Correlation between levels of anti-A/B antibodies as
detected by surface plasmon resonance using the Biacore® device
and levels of B cell subsets in CVID patients. Anti-A/B antibodies were
determined using surface plasmon resonance (SPR) technology with synthetic
blood group A/B trisaccharides coupled to the CM-5 Biacore® chip by amine
binding, antibody titers are expressed as resonance units (RU). Peripheral B
cell subsets were determined by three-color-flow cytometry, results are
depicted as the percentage of total number of CD19+ B lymphocytes.
Horizontal lines indicate the normal range of B cell subsets as determined in
134 healthy individuals (upper panel: 5th percentile; middle and lower panel:
upper line, 95th percentile, lower line, 5th percentile). The
Bravais–Pearson-correlation coefficient was calculated to determine a
statistically significant correlation between two parameters at a level of
P<0.05.
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FIGURE 3 | Detection of anti-A/B IgG- and IgM-antibodies by flow
cytometry. The anti-A/B IgG and IgM mean fluorescence intensity (MFI)
histograms of a representative CVID patient (bold lines) with no anti-A/B IgG
(A,B), no anti-A IgM but with anti-B IgM present (C,D), and a healthy individual
(hatched histograms) with anti-A/B IgG (A,B) and anti-A/B IgM present (C,D)
are depicted. Background binding of fluorescence-labeled anti-IgG and anti-IgM
was assessed using AB serum [(A–D), filled histograms] containing no or only
low levels of anti-A/B IgG-(A,B) and IgM-antibodies (C,D). The X-axis
represents the MFI given on a logarithmic scale and the Y-axis the cell number
on a linear numeric scale. (Continued)
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FIGURE 3 | Continued
Defective anti-A/B IgG (E) but normal IgM (F) antibody response in patients with
CVID and controls (healthy Co) as examined by flow cytometry. Background
binding of fluorescence-labeled anti-IgG and anti-IgM to the erythrocytes was
assessed in the presence of an AB serum containing no or only low levels of
anti-A/B antibodies. Box plot diagrams show anti-A/B IgG (E) and IgM (F)
antibodies in serum with the median of the study group represented by a cross,
the interquartile range (IQR) represented by the box, 5- and 95-percentile
values represented by the whiskers, and minimum and maximum values
depicted by circles. The non-parametric Mann–Whitney U-test (two-sided P
value) was used for statistical comparison between patients and healthy control
subjects.
CVID Patients Produce No Blood Group Anti-A/B
IgG as Detected by Surface Plasmon Resonance
Using the Biacore® Device
To further discriminate between IgM and IgG anti-A/B response
we added anti-IgM and anti-IgG antibodies to the SPR assay as
described in the Section “Materials and Methods.” An additional
binding of the anti-IgM and anti-IgG antibodies to the respective
anti-A/B antibodies present in the test sample caused ameasurable
rise in the RU value that was proportional to the amount of
IgM/IgG-anti-A/B antibodies present in the sample. Commer-
cially available anti-blood group A/B mAbs in a concentration
of 50 µg of anti-A IgM mAbs gave 2500 RU in this assay, while
the limit of detection was observed at 300 ng of anti-A IgM, and
40 µg of anti-B IgM mAbs gave a maximum 1000RU, while the
limit of detection in this case was observed at 640 ng. When the
assaywas calibratedwith 10 µg of anti-A IgGmAbs amaximumof
15,000 RU were measured, while the limit of detection for anti-A
IgG was observed at 100 ng.
While 90% of the healthy individuals presented with easily
detectable (100 RU) anti-A/B IgM and IgG antibodies, anti-
A/B IgG antibodies were undetectable or very low (<100 RU)
in all 20 CVID patients investigated (Figure 4, upper panel),
Six of these 20 patients also had very low to undetectable anti-
A/B IgM-antibodies (CVID_M_low in Figure 4, lower panel),
while levels of anti-A/B IgM-antibodies in the remaining patients
(CVID_M_normal in Figure 4, lower panel) were comparable to
the healthy control group.
Affinity of Blood Group Anti-A/B IgM Antibody
Binding to Blood Group A/B Trisaccharide
Antigens is Not Altered in CVID Patients
The erythrocyte aggregation assay based on theDiamed-IDMicro
Typing System as well as the flow cytometric method to quantify
binding of anti-A/B antibodies to fixed human A or B red blood
cells (ABO-FACS) cannot rank anti-A/B antibodies according to
their strength of reaction with the corresponding blood group
A/B trisaccharide antigens. In order to compare affinity of the
anti-A/B IgM antibodies, we depleted serum IgG from healthy
individuals with high blood group anti-A or B isoagglutinins with
protein A- and protein G-affinity columns and measured the on
and off rates of the anti-AB IgMantibodies to the respective trisac-
charide immobilized on the CM-5 chip. For these experiments,
amine-coupling of the trisaccharides to the surface of the CM5
sensor chipwas used in order to guarantee physiological condition
of binding (16–18). We found no difference in association (ka)
and dissociation rate (kd) between CVID patients and controls
depleted of IgGwhen serawere diluted tomatchwith 700 RU (data
not shown).
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FIGURE 4 | Isotype-specific measurement of anti-A/B antibodies by
surface plasmon resonance using the Biacore® device in healthy
controls, patients with CVID and XLA patients (Agamma). The amount
of IgG- (upper panel) and IgM- (lower panel) anti-A/B antibodies present in the
serum sample are depicted as resonance units (RU) using box plot diagrams,
the median of the study group is represented by a cross, the interquartile
range (IQR) is represented by the box, 5- and 95-percentile values are
represented by the whiskers, and minimum and maximum values are
represented by circles. The 95% confidence interval for the median calculated
according to McGill et al. (21) is indicated by horizontal bars. The
non-parametric Mann–Whitney U-test (two-sided P value) was used for
statistical comparison between patients and healthy controls. CVID_M_low,
CVID patients with very low to undetectable anti-A/B IgM-antibodies;
CVID_M_normal, CVID patients with anti-A/B IgM-antibody titers that were
comparable to the healthy control group.
Impaired Blood Group Anti-A/B Antibody
Response in CVID Patients is Associated with
Defective IgM-Antibody Response to
Pneumococcal Polysaccharides
Antibodies against 23-valent PnP were determined by ELISA
in 32 of the 34 CVID patients in order to find a correlation
between the immune response to PnPs andblood groupABOanti-
gens, because ABO- and PnP-antigens share similar carbohydrate
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moieties (22–24). Interestingly, among the 32 CVID patients in
whom both PnP antibodies and isoagglutinins could be tested,
nine patients showed no detectable isoagglutinins and no or only
very low blood group anti-A/B antibodies in the SPR assay and
also showed no PnP-specific IgM-antibody response. Among the
remaining 23 CVID patients with detectable blood group anti-
A/B isoagglutinins, only 15 showed no anti-PnP IgM-antibodies
(P= 0.042, Chi-squared analysis). In addition, there was a trend
toward a positive correlation between the levels of the patients’
anti-A/B IgM-response as measured using SPR and their serum
anti-PnP IgM, and low levels of total serum IgMwere significantly
correlated with low levels of anti-A/B IgM-antibodies (Figure 5).
Typical for all CVID patients was the incapability to produce PnP-
specific IgG (Table 1), which was in accordance with a defective
IgG-response to blood group ABO antigens.
Discussion
Common variable immunodeficiency (CVID) comprises a het-
erogeneous group of patients with a multitude of immunological
abnormalities that have in common a severely impaired anti-
body production with altered isotype-switch and defective affinity
maturation of the antibodies produced (5). Dependent on the
underlying defect, B cell activation and development might be
compromised at different levels enabling B cells of certain patients
with CVID to mount an IgM antibody response, while B cells of
other CVID patients withmore severe defects cannot produce any
antibodies at all (25). Due to the profound antibody deficiency,
the patients suffer from severe susceptibility to infections, and the
demonstration of defective IgG antibody production provides the
indication for immunoglobulin replacement therapy (26), as was
proposed by an IUIS expert committee alreadymany years ago (5).
The present study investigated the capability of CVID patients’
B cells to respond to blood group ABO antigens and shows
that 100% of the patients that receive long-term immunoglobulin
replacement therapy based on their inability to produce IgG anti-
bodies following vaccination or infection (26) also have a defect
in IgG antibody formation against ABO blood group antigens,
thus providing an additional diagnostic parameter of possible
clinical-therapeutic relevance.
Anti-ABO antibodies are thought to be natural antibodies
produced by all individuals with a functional immune system
(14). Their immunologically active epitopes share carbohydrate
moieties and appear first in infants at the age of 3–6months when
the developing immune system can react with microorganisms
and environmental antigens that have similar carbohydrate epi-
topes as the blood group ABO antigens (22–24). Certain debate
exists, however, whether anti-AB antibodies completely fulfill
the criteria of natural antibodies (27). Natural antibodies were
described to be encoded by germline variable (V) genes, show
no somatic mutations and are produced predominantly by CD5+
B1 cells, at least in the mouse, although certain splenic CD5  B2
cells were also capable of producing natural antibodies (28, 29).
Natural antibodies are mostly of the IgM isotype, are therefore
polyreactive and show a wide range of binding avidities (14, 30).
High resolution crystallography has shown that anti-carbohydrate
antibodies in germline configuration can recognize a range of
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FIGURE 5 | Correlation between reduced blood group anti-A/B IgM
antibodies and defective IgM-antibody response to pneumococcal
polysaccharides (upper panel) or reduced serum IgM levels (lower
panel) in CVID patients. Serum IgM antibodies against 23-valent
pneumococcal polysaccharides (PnP–IgM) were determined by ELISA, serum
blood group anti-A/B IgM antibodies were assessed using isotype-specific
surface plasmon resonance technology, serum IgM levels were measured by
nephelometry. Results are depicted as reciprocal serum titer (for PnP–IgM),
resonance units (RU, for anti-A/B IgM-antibodies), and mg/dl (for serum IgM).
The Bravais–Pearson-correlation coefficient was calculated to determine a
statistically significant correlation at a level of P<0.05.
structurally related carbohydrate epitopes (22). A repertoire of
pre-existing ‘natural antibodies’ might exist in healthy individu-
als in the absence of immune stimulation which is encoded by
a relatively small number of germline progenitors recognizing
carbohydrate moiety with a define shape (31), although a second
stage of selection for antibodies directed against blood groupABO
antigens with higher affinity cannot be excluded at present.
Natural antibody formation has up to now not been studied
in greater detail in patients diagnosed with CVID. This study
shows that a defective IgG antibody response to protein and
polysaccharide antigens that is characteristic for patients with
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CVID (26) is accompanied by a defect in the formation of natural
IgG antibodies such as anti-A/B IgG-antibodies. Of the 34 patients
investigated, we found only nineCVIDpatients with no detectable
anti-A/B antibodies at all, similar to the eight patients with XLA
that had no detectable peripheral B cells due to btk-deficiency. The
remaining 25 patients showed detectable anti-A/B antibodies that
were of the IgM isotype. In contrast, healthy individuals showed
both anti-A/B IgM and IgG responses. These results are in accor-
dance with previous studies showing defects in class switching in
CVID patients (25, 26, 32). Interestingly, the association rate (ka)
and dissociation rate (kd) of blood group specific anti-A/B IgM
antibodies binding to defined blood group A/B trisaccharides was
normal in CVID patients, indicating that the majority of CVID
patients might produce blood group specific IgM antibodies that
are functional intact.
The defective IgM response against A/B blood group antigens
observed in CVID patients was accompanied by defective IgM
antibody formation against pneumococcal capsular polysaccha-
rides as well. One reason for the failure of CVID B cells to respond
to pneumococcal and blood group polysaccharides could be insuf-
ficient triggering of TLRs and their signaling pathways, as TLR-
activation is critical for T-independent antibody responses (33).
CVID B cells were shown to have impaired responses to TLR7 and
TLR9 agonists including poor cell proliferation, loss of cytokine
production, and failure to produce and secrete IgG and IgA (34,
35). IFN-α could restore TLR7- and TLR9-triggered functional
responses in B cells of CVID subjects with >0.5% peripheral
isotype-switched memory B cells (34). An alternative explanation
for the observed association between anti-A/B and pneumococcal
IgM-antibodies could be a general decrease in IgM production
as is reflected by the low level of total serum IgM in most CVID
patients.
Patients with predominantly antibody deficiency who have a
long history of clinical disease, in particular recurrent infections
of the lower respiratory tract, are well known to be prone to
developing organ damage such as chronic lung disease, which
determines their long-term prognosis (36). Increased awareness
for PID hasmade earlier diagnosis and initiation of adequate ther-
apy in PID patients feasible, so that more and more patients with
predominantly antibody deficiency lack a long history of clinical
disease, making it necessary to initiate immunoglobulin replace-
ment therapy based on laboratory findings rather than patient
history. Detection of impaired IgG antibody formation has been
suggested as a laboratory parameter to facilitate the decision on
early immunoglobulin replacement in hypogammaglobulinemic
patients (26). Currently used diagnostic criteria for CVID, e.g.,
the criteria proposed by an IUIS expert committee (5), the most
commonly used European Society for Immunodeficiencies/Pan
American Group for Immunodeficiency (ESID/PAGID) defini-
tion of CVID (3) or the 2014 diagnostic criteria for the ESID reg-
istry (4) propose defective isoagglutinins and impaired antibody
formation after vaccination or infection as equivalent criteria. SPR
analysis proved to be the most specific and sensitive method for
the detection of anti-blood groupA/B IgG antibodies and applying
this method a pronounced defect in IgG antibody production
could be demonstrated and defined in all CVID patients tested.
As can be seen in Figure 1, conventional methodology such as
the erythrocyte aggregation assay based on the Diamed-IDMicro
Typing Systemwas unable to detect defective antibody production
in the majority of CVID patients, as a considerable proportion
(approximately 2/3) of these patients can produce normal levels
of anti-A/B IgM antibodies. Furthermore, SPR analysis of anti-
A/B antibodies can be applied to ascertain early diagnosis of IgG
antibody deficiency in CVID patients, while at present, antibody
failure has to be proven by the lack of response to vaccination. The
clinical application of SPR analysis for the diagnosis of antibody
deficiency certainly requires further development. Comparable
efforts have been undertaken for the application of this method in
the rapid quantitation of blood group antibodies (16), and more
recently a 96-well-plate format has been presented for clinical
applications of SPR in serum antibody quantification (37). In
contrast to microtyping, both flow cytometry and SPR can detect
anti-A/B antibodies in an isotype-specific manner. In addition
to a greater sensitivity in detecting anti-A/B antibodies, further
advantages of the SPR method include the use of molecularly
well defined, standardized blood group antigens as compared to
the interindividual variations in donor erythrocytes used as the
particulate antigen in flow cytometry, and the ability to detect
biologically relevant antibody specificities, as the carbohydrate
antigens are presented in a physiological manner.
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